Clinical Trials Logo

Alpha 1-Antitrypsin clinical trials

View clinical trials related to Alpha 1-Antitrypsin.

Filter by:
  • None
  • Page 1

NCT ID: NCT06029543 Not yet recruiting - COPD Clinical Trials

Permian Health Women's Lung Health Study

WLHS
Start date: December 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this cross-sectional observational study is to estimate the prevalence of lung function impairment as measured by spirometry in a population of Gambian women aged 15 and older. The main question[s] it aims to answer are: - What is the prevalence of lung function impairment in Gambian women - What is the prevalence of eosinophilic inflammation in Gambian women Consenting participants will undergo - Spirometry - Fractional exhaled nitric oxide (FENO) testing - α1-antitrypsin testing in patients with lung function impairment as assessed by spirometry

NCT ID: NCT03188601 Completed - GVHD Clinical Trials

α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD

AATGVHD-MARK
Start date: January 27, 2018
Phase:
Study type: Observational [Patient Registry]

Create a personalized time and context curve of patient circulating α1-antitrypsin (AAT) levels and functions before hematopoietic stem cell transplantation and throughout progression into GVHD. PRIMARY ENDPOINT 1. Serum AAT levels and activity, before myeloablative preconditioning, as well as on days (-3),0,7,14,28 from HSCT and every 21 days thereafter. SECONDARY ENDPOINTS 1. Correlation between AAT patterns and: - Circulating immune cell activation profiles on day of ablation, 28 days from HSCT and once GVHD is diagnosed. - Patient survival - Liver function tests - GVHD grade: skin manifestations, weight, GI and liver histopathology - Graft-versus-leukemia effect